Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.

To evaluate the effect of liraglutide and NPH on blood glucose fluctuations in patients with newly diagnosed type 2 diabetes mellitus (T2DM).
A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group. They were treated for 12 weeks. The values of CGM, HbA1C, and BMI were measured and compared before and after treatment.
FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment. In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05). Patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects than in the NPH group (p<0.05). The incidence of hypoglycemia episode in the liraglutide group was significantly lower than in the NPH group (p<0.05).
Liraglutide achieved improvements in overall glycemic control similar to NPH in patients with newly diagnosed T2DM. Liraglutide was associated with less glucose fluctuation than NPH treatment as assessed by CGM. In addition, patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects, a lower incidence of hypoglycemia, and some weight reduction.
AuthorsZejun Ma, Rui Chen, Yan Liu, Pei Yu, Liming Chen
JournalInternational journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 53 Issue 11 Pg. 933-9 (Nov 2015) ISSN: 0946-1965 [Print] Germany
PMID26365337 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Blood Glucose
  • Hemoglobin A, Glycosylated
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human
  • Insulin, Isophane
  • Liraglutide
  • Metformin
  • Adult
  • Aged
  • Biomarkers (blood)
  • Blood Glucose (drug effects, metabolism)
  • Body Mass Index
  • China
  • Diabetes Mellitus, Type 2 (blood, diagnosis, drug therapy)
  • Drug Therapy, Combination
  • Female
  • Gastrointestinal Diseases (chemically induced)
  • Hemoglobin A, Glycosylated (metabolism)
  • Humans
  • Hypoglycemia (chemically induced)
  • Hypoglycemic Agents (adverse effects, therapeutic use)
  • Insulin, Isophane (adverse effects, therapeutic use)
  • Liraglutide (adverse effects, therapeutic use)
  • Male
  • Metformin (adverse effects, therapeutic use)
  • Middle Aged
  • Monitoring, Ambulatory (methods)
  • Predictive Value of Tests
  • Prospective Studies
  • Time Factors
  • Treatment Outcome
  • Waist Circumference

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: